Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
24200264

DOI
10.5588/ijtld.13.0423

Indexing Status
Subject indexing assigned by NLM

MeSH
Antitubercular Agents /administration & dosage /adverse effects /economics; Computer Simulation; Cost-Benefit Analysis; Directly Observed Therapy /economics; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Hospital Costs; Humans; Isoniazid /administration & dosage /adverse effects /economics; Latent Tuberculosis /diagnosis /drug therapy /economics; Models, Economic; Quality-Adjusted Life Years; Rifampin /administration & dosage /adverse effects /analogs & derivatives /economics; Time Factors; Treatment Outcome; United States

AccessionNumber
22013049439

Date bibliographic record published
27/02/2014